We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
+$60.4M
Cap. Flow
-$61.1M
Cap. Flow %
-5.98%
Top 10 Hldgs %
49.68%
Holding
183
New
37
Increased
35
Reduced
45
Closed
53

Top Buys

Rank Stock Value
1
BCOM
B Communications Ltd
BCOM
+$95.7M
2
BIIB icon
Biogen
BIIB
+$20.4M
3
CELG
Celgene Corp
CELG
+$10.3M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$7.22M
5
ATXS
Astria Therapeutics
ATXS
+$5.62M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$18.8M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.5M
4
AMGN icon
Amgen
AMGN
+$9.61M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 50.75%
2 Technology 3.95%
3 Utilities 1.35%
4 Industrials 0.96%
5 Consumer Discretionary 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTO
126
DELISTED
Altamira Therapeutics Ltd
CYTO
$316K 0.03%
1
-1
-50% -$415K
PRGO icon
127
Perrigo
PRGO
$1.4B
$246K 0.02%
273
-18,127
-99% -$3.46M
CNCE
128
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$236K 0.02%
15,858
-359,142
-96% -$5.47M
TTHI
129
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$148K 0.01%
70,273
-202,633
-74% -$1.42M
ADVM
130
DELISTED
Adverum Biotechnologies
ADVM
– –
-6,000
Closed -$2.43M
ARCT icon
131
Arcturus Therapeutics
ARCT
$164M
– –
-29
Closed -$1K
ASMB icon
132
Assembly Biosciences
ASMB
$498M
– –
-8,333
Closed -$1.32M
ASND icon
133
Ascendis Pharma A/S
ASND
$16B
– –
-70,000
Closed -$1.22M
ATRA icon
134
Atara Biotherapeutics
ATRA
$75.5M
– –
-2,543
Closed -$2.64M
AZN icon
135
AstraZeneca
AZN
$263B
– –
-86,637
Closed -$5.93M
BKNG icon
136
Booking.com
BKNG
$149B
– –
-45,500
Closed -$2.12M
BLRX
137
BioLineRX
BLRX
$12.3M
– –
-322
Closed -$408K
CARM
138
DELISTED
Carisma Therapeutics
CARM
– –
-4,356
Closed -$777K
CLDX icon
139
Celldex Therapeutics
CLDX
$2.99B
– –
-7,000
Closed -$2.93M
CLLS
140
Cellectis
CLLS
$277M
– –
-50,000
Closed -$1.73M
CVS icon
141
CVS Health
CVS
$133B
– –
-42,260
Closed -$4.36M
ELDN icon
142
Eledon Pharmaceuticals
ELDN
$261M
– –
-903
Closed -$1.65M
ESPR
143
DELISTED
Esperion Therapeutics
ESPR
– –
-36,000
Closed -$3.33M
HRTX icon
144
Heron Therapeutics
HRTX
$93.9M
– –
-79,900
Closed -$1.16M
ITB icon
145
iShares US Home Construction ETF
ITB
$2.26B
– –
-76,000
Closed -$2.15M
IWM icon
146
iShares Russell 2000 ETF
IWM
$79.8B
– –
-56,100
Closed -$6.98M
KMDA icon
147
Kamada
KMDA
$412M
– –
-293,727
Closed -$5.17M
MNKD icon
148
PUT
MannKind Corp
MNKD
$1.21B
– –
-600
Closed -$1.56M
NBIX icon
149
Neurocrine Biosciences
NBIX
$16.8B
– –
-75,000
Closed -$2.98M
PBYI icon
150
Puma Biotechnology
PBYI
$404M
– –
-13,796
Closed -$3.26M
4 5
6
7 8

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sphera Funds Management held 183 positions worth $1.02B, up 6.3% from $961M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management withdrew a net $61.1M in Q2 2015, closing 53 positions and reducing 45 holdings. Its most notable exit was Endo International plc, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in B Communications Ltd worth $6.45M.

  • Sphera Funds Management's largest Q2 2015 buy was B Communications Ltd: 5,977,000 shares worth $6.45M.
  • Sphera Funds Management added most to Biogen in Q2 2015, an estimated $20.4M increase.
  • Sphera Funds Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $13.9M.
  • Sphera Funds Management fully exited Endo International plc in Q2 2015, selling an estimated $18.8M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.02B portfolio in Q2 2015.
  • Sphera Funds Management opened 37 new positions and closed 53 in Q2 2015.
  • Sphera Funds Management's portfolio value rose 6.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.